Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Fluciclovine PET/CT in Multiple Myeloma
NCT06103838Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2024
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluciclovine f 18 in multiple myeloma (MM), sponsored by National Cancer Institute. Primary endpoint: Concordance between 18F-fluciclovine PET/CT and 18F-FDG PET/CT. Started Mar 2024; status: recruiting.
02
Drugs
fluciclovine f 18
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06103838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06103838.